Alan I. Edrick
Analyst · Benchmark Company
Thank you, Deepak. Our ongoing effort to deliver meaningful revenue and earnings growth through higher-margin growth initiatives and operating improvements continues to prove successful. Let's review in greater detail the financial results for the first quarter of the fiscal year before discussing our updated fiscal 2015 guidance. As mentioned earlier, our revenues in the first quarter increased 6% over Q1 of fiscal '14. This was primarily due to the 17% revenue growth in the quarter in our Security division resulting from strength in our core baggage and parcel inspection products, new product launches and the partial fulfillment of the large FMS contract entered into in June of 2014. Our Opto division's revenues decreased 3% as a result of lower contract manufacturing sales, given the tough comp that Deepak just alluded to, due to a large international stocking order in the prior year, offset partially by strong intercompany sales. Revenues in our Healthcare division increased a modest 4%, resulting from the acquisition of the cardiology business that Deepak just mentioned. While sales in North America to the hospital market improved, softness in Europe offset such gains. Healthcare bookings picked up with a book-to-bill ratio of 1.2 in Q1, providing a cautious degree of optimism. Our gross margin came in at 34%, an increase of 110 basis points as compared to Q1 in the prior year. This improvement was driven by a number of factors, including, one, the growth of Security revenues and a favorable product mix; and, two, the impact of the decrease in revenue in our Opto Division, which typically carries the lowest gross margin in the company's 3 divisions. As mentioned on previous calls, the margin will fluctuate from period-to-period based on revenue mix amongst other factors. Moving to OpEx. In Q1 of fiscal '15, SG&A as a percentage of sales decreased to 20.2% as compared to 20.5% in the prior year. In absolute dollars, the increase in SG&A of $2 million supported the 6% sales growth. Our goal continues to be to hold the SG&A growth rate below the rate of sales growth, though individual quarters may vary from this. We remain committed in all of our divisions to increasing efficiencies and managing our cost structure prudently. We continue to invest significant resources in R&D to enhance our Security and our Healthcare product offerings. Our R&D spending of $12.7 million in Q1 was up 15% from the prior year, mainly due to increased spending to support our next generation of products in our Security division. We expect an elevated level of R&D spending in fiscal '15 as we develop innovative technologies to broaden our product offerings and enhance future growth. Our effective tax rate for Q1 was 28.8% as compared to 29% in the same quarter of the prior year. Our provision for income taxes is dependent on a mix of income from U.S. and foreign locations, due to tax rate differences among countries, as well as the impact of permanent taxable differences, tax elections and valuation allowances, amongst other items. As we move down the income statement, our Q1 GAAP diluted EPS was $0.55, a new record, and the Q1 non-GAAP EPS per diluted share, which excludes restructuring and other charges, was $0.57, also a new record, compared to $0.46 in the comparable prior year period, a 24% improvement. I'll next turn to a discussion of our operating margin, excluding restructuring and other charges. The Q1 adjusted operating margin was 8% compared to 7.1% in the prior year. The Security division reported an operating margin of 15.2%, improving from 13.6% in Q1 last year. As mentioned in our previous calls, we expected to see a sequential increase in Opto's operating margin. This, again, proved to be true, as Opto's adjusted operating margin increased from 6.2% in Q4 to 6.5% in Q1. And finally, in Healthcare, given the flat organic sales, we recorded an awesome growth for the quarter [ph]. As you may recall, Healthcare is our highest contribution margin business, and thus the bottom line is extremely sensitive to revenue increases and decreases. For the company overall, adjusted EBITDA margins during Q1 increased year-over-year from 16.1% to 18.8%, driven mainly by strength in our Security division. Moving to cash flow. For Q1 of fiscal '15, we reported operating cash flow of $31.5 million; capital expenditures totaled approximately $3.1 million in Q1; while depreciation and amortization was $17.7 million. Days sales outstanding, or DSO, was 65 days in Q1 of fiscal '15 compared to 91 days last year. Our level of DSO frequently fluctuates significantly from period to period. We repurchased nearly 400,000 shares through our share repurchase program and had settlements totaling $24.9 million. Our balance sheet is strong, and our leverage ratio remains well below 1x. Our credit facility continues to provide the company with flexibility to execute our business plan. And finally, turning to our fiscal 2015 guidance. We are increasing our revenue guidance in fiscal '15 to be between $970 million and $995 million. We're slightly increasing our guidance for fiscal '15 non-GAAP diluted earnings per share, which excludes the impact of impairment, restructuring and other charges, to $3.53 to $3.76. We currently believe the sales and earnings guidance reflects reasonable estimates. However, actual sales and earnings could vary from this range because of the risks and uncertainties applicable to our business and industry. During the past few years, we have built a strong foundation for growth and have consistently delivered a strong bottom line, along with significant operating and free cash flow. Our investments have enabled us to become the leader in turnkey screening solutions and allowed us to introduce innovative products and services to the market. We look forward to sharing our progress on upcoming calls. Thank you for listening to this call, and at this time, we'd like to open the call to questions.